GPPGPAG Peptide Ameliorates Memory Impairment via Dendritic Density

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current compounds for ameliorating memory disorders such as Alzheimer's disease and dementia are inadequate in effectively addressing neural cell dysfunction and death, leading to significant challenges in treating these conditions.

Innovation Solution

A peptide with the amino acid sequence GPPGPAG is developed, which is used to create a pharmaceutical composition that can be administered to subjects with memory disorders, aiming to ameliorate these conditions by enhancing dendritic density and presynaptic density, and improving memory recognition.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional compounds (4'-demethyl nobiletin, 4'-demethyl tangeretin, low-dose pioglitazone) are used for treating memory disorders, then some therapeutic effect is achieved, but the treatment is inadequate for effectively addressing neural cell dysfunction and death

Engineering Contradiction:

Improveeffectiveness in addressing neural cell dysfunction and deathVSAvoidadequacy of treatment coverage

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention changes the chemical parameter from small molecule compounds to a specific peptide sequence (GPPGPAG), fundamentally altering the therapeutic agent's properties to achieve better effectiveness against neural cell dysfunction and death while maintaining treatment adequacy

Inventive Principle:

Principle #35Parameter changes

2Quantity of substance

If a peptide consisting of amino acid sequence GPPGPAG is administered, then dendritic density and presynaptic density increase significantly, but the complexity of the pharmaceutical composition increases

Engineering Contradiction:

Improvedendritic density and presynaptic densityVSAvoidcomplexity of pharmaceutical composition

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The invention segments the therapeutic approach by using a short, specific peptide sequence (GPPGPAG) rather than complex compounds, achieving significant increases in dendritic and presynaptic density while keeping the pharmaceutical composition relatively simple through targeted amino acid sequence design

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS10660935B2Methods for ameliorating memory impairment in a memory disorder caused by neuronal cell death or Abeta aggregation using a peptide

Publication Date: 2020.05.26 JAPAN BIO PROD

AI summary

A peptide consisting of an amino acid sequence of GPPGPAG (SEQ ID NO: 1) is disclosed. According to the present invention, a novel compound for improving memory disorder is provided.